MedTrace Logo

Hypofractionation for Prostate Cancer in Africa: A Feasibility Study

NCT06950307 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2025-04-30

No results posted yet for this study

Summary

Hypofractionated radiotherapy (HFRT) is a technique that delivers a higher radiation dose per treatment fraction over a shorter overall number of fractions, thus reducing the number of radiotherapy visits required to complete a course of radiation therapy. HFRT significantly alleviates the burden of transportation, accommodation, and income loss for patients while mitigating the strain on already limited healthcare personnel and infrastructure resources.

Several randomized studies conducted in Europe and the USA have demonstrated that HFRT for prostate cancer is non-inferior to conventional radiotherapy in terms of toxicity and treatment outcomes. HypoAfrica Prostate Cancer is a multi-center study that aims to explore the feasibility of implementing moderate HFRT for the treatment of localized prostate cancer in Africa. In particular, this study will evaluate the gastrointestinal and genitourinary toxicities in prostate cancer patients for up to two years post-completion of HFRT.

Conditions

Interventions

RADIATION

Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer patients

Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer will be treated with 20x3 Gray (Gy), 5 days/week

RADIATION

Hypofractionated radiotherapy for high-risk prostate cancer patients

Hypofractionated radiotherapy for high-risk prostate cancer will be treated with 20x3.1 Gy, 5 days/week

Sponsors & Collaborators

  • Inkosi Albert Luthuli Central Hospital

    collaborator UNKNOWN

  • Erasmus Medical Center

    collaborator OTHER

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • Nigeria Sovereign Investment Authority-Lagos University Teaching Hospital Cancer Center (NLCC)

    collaborator UNKNOWN

  • Muhimbili University of Health and Allied Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2026-03-01
Completion
2029-03-01

Countries

  • Nigeria
  • South Africa
  • Tanzania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06950307 on ClinicalTrials.gov